Across CAR-T, ADCs, and radioligand therapy, severe toxicity tends to converge on a recognizable pattern: a short, high-acuity period in which multiple organ systems become unstable together and the patient's trajectory can turn quickly in either direction. Conventional pharmacovigilance, organized around discrete adverse events on a periodic cadence, is not designed to see this window as a single clinical entity.

We name it the Acute Multi-Organ Instability Phase (AMOIP) because naming it changes the governance. AMOIP is not a regulatory category; it is a clinical reference point that tells a safety program where its attention, its coverage, and its decision-making speed have to concentrate.

Treating AMOIP as a defined window — with pre-agreed monitoring intensity, escalation logic, and a named physician positioned to adjudicate in real time — is the difference between reconstructing what happened afterward and governing it as it unfolds. It is the clinical core of how we design high-acuity safety oversight.